Cochrane Evidence Synthesis and Methods ►

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to determine benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.

This is a protocol.

Health topics:

Cancer > Haematological malignancies > Multiple myeloma

Published:

26 April 2020

Authors:

Langer P, Monsef I, Scheid C, Skoetz N

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Langer P, Monsef I, Scheid C, Skoetz N. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No.: CD013595. DOI: 10.1002/14651858.CD013595.